GC Biopharma Stake in Green Cross Medical Science Dilutes to 47% from 51.6% Following Warrant Exercises
GC Biopharma filed a large shareholding report disclosing that its stake in Green Cross Medical Science decreased by 4.59 percentage points from 51.59% to 47.00%.
The decline was driven by an increase in total shares outstanding due to warrant exercises. A total of 2,221,105 new shares were listed in May and June 2026, raising the outstanding share count to 23,963,031.
Changes among special relations include an increase of 43,500 shares by inside director Kim Yeon-geun through stock bonus and open market purchases, an increase of 4,000 shares by director Kim Won-ki, and a decrease of 2,400 shares due to the resignation of director Eom Hyun.
[AI Summary]GC Biopharma's majority stake in Green Cross Medical Science was diluted to 47% following a 10% increase in outstanding shares from warrant exercises. The controlling shareholder retains influence but with reduced ownership. Capital deployment purpose is unspecified, warranting a neutral stance.